Maternal and health care determinants of preconceptional use of folic acid supplementation in France: results from the 2010 National Perinatal Survey
Article first published online: 10 SEP 2013
© 2013 Royal College of Obstetricians and Gynaecologists
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 120, Issue 13, pages 1661–1667, December 2013
How to Cite
Maternal and health care determinants of preconceptional use of folic acid supplementation in France: results from the 2010 National Perinatal Survey. BJOG 2013; DOI:10.1111/1471-0528.12414., , , , .
- Issue published online: 11 NOV 2013
- Article first published online: 10 SEP 2013
- Manuscript Accepted: 29 JUN 2013
- Bettencourt Foundation
- Chronic diseases;
- fertility treatments;
- folic acid;
- maternal characteristics;
- pregnancy planning;
To estimate the national prevalence and analyse the factors associated with preconceptional folic acid supplementation, including maternal sociodemographic characteristics, region of residence, birth control use and chronic diseases requiring medical care before conception.
Cross-sectional population-based study.
All maternity units in France.
A nationally representative sample of women giving birth in 2010 (n = 12,646).
Data came from mothers' interviews 2–3 days after delivery. Statistical analyses included multivariable logistic regressions.
Main outcome measure
Folic acid supplementation starting at least 1 month before conception.
14.8% (95% confidence interval [95% CI] 14.2–15.4) of women used folic acid before pregnancy; this percentage varied from 10.4% to 18.7% across regions. Supplementation was more frequent in primiparae, French citizens, women with higher educational levels and those needing medical monitoring or treatment before conception. Women who stopped contraception to become pregnant (75% of our population) used folic acid more often (intrauterine device or implant: 19%, pill: 17%, other methods which did not need medical monitoring: 17%) than other women (7%). The adjusted odds ratios were 3.3 (95% CI 2.6–4.3) for intrauterine device and implant, 2.2 (95% CI 1.8–2.6) for pill and 1.9 (95% CI 1.5–2.4) for other methods, compared with women who did not use birth control.
The absence of preconceptional folic acid supplementation for most women, even those needing consultations with healthcare professionals before pregnancy, shows that campaigns to promote folic acid supplementation should address not only women but also healthcare professionals involved in birth control and obstetric care before pregnancy.